Apalutamide Active in Castration - Resistant Prostate Cancer
Apalutamide prolongs metastasis - free survival in non - metastatic castration - resistant prostate cancer
Publication date: Available online 21 February 2018 Source:The Journal of Molecular Diagnostics Author(s): Anieta M. Sieuwerts, Bianca Mostert, Michelle van der Vlugt-Daane, Jaco Kraan, Corine Beaufort, Mai Van, Wendy J.C. Prager, Bram De Laere, Nick Beije, Paul Hamberg, Hans M. Westgeest, Metin Tascilar, Luc Y. Dirix, Wendy Onstenk, Ronald de Wit, Martijn P. Lolkema, Ron H.J. Mathijssen, John W.M. Martens, Stefan Sleijfer Recent reports have emphasized the clinical relevance of detecting the androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs). Our aim was to set up a validated multicenter pipelin...
Publication date: Available online 22 February 2018 Source:Pathology - Research and Practice Author(s): Nam Jin Yoo, Min Sung Kim, Ju Hwa Lee, Chang Hyeok An, Sug Hyung Lee
(Reuters Health) - Men with prostate cancer who get the gland removed may be just as likely to suffer after-effects like erectile dysfunction and urinary incontinence with robotic surgery as with other operations, a UK study suggests.
The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.
ConclusionPatients who have undergone prostate biopsy and treatment decision-making for Pca experience a decline in HRQoL. Choosing treatment with a curative intent was associated with greater decline in HRQoL. Interventions aimed at optimism and decision self-efficacy could be helpful to reduce HRQoL impairment around the time of prostate biopsy and treatment decision-making.
CARY, N.C. (February 21, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected by the Janssen Pharmaceutical Companies of Johnson&Johnson1 to be in the limited distribution network for ERLEADA™ (apalutamide), the first FDA-approv...
Series Type : Expression profiling by array ; Expression profiling by high throughput sequencingOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.
Contributors : Marcin Cieslik ; Yajia ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe goal of this analysis is to profile AR-regulated genes, especially non-coding RNAs in three androgen sensitive prostate cancer cell lines, MDA-PCA-2B, LNCaP and VCaP. The two cell lines were serum-starved first, followed by dihydrotestosterone (DHT) stimulation or treated with Enzalutamide (AR inhibitor) without starvation. Transcriptome profiling was generated by RNA-sequencing from polyA-selected RNA. These experiments are followed by knock-down experiments of AR and ARlnc1 in MDA-PCA-2B, ...
Contributors : Filippo Cortesi ; Gloria Delfanti ; Arianna Calcinotto ; Francesca Gorini ; Ferdinando Pucci ; Michele De Palma ; Andrea Grilli ; Alessandra Recchia ; Silvio Bicciato ; Matteo Bellone ; Giulia Casorati ; Paolo DellabonaSeries Type : Expression profiling by arrayOrganism : Mus musculusTo investigate the impact of the iNKT cells on the tumor-infiltrating leukocytes in TRAMP mouse prostate cancer.